Suggested remit: To appraise the clinical and cost effectiveness of inhaled treprostinil within its marketing authorisation for treating pulmonary hypertension caused by interstitial lung disease.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6459
Provisional Schedule
- Committee meeting: 1:
- 18 December 2025
- Expected publication:
- 04 March 2026
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- Ferrer International (inhaled treprostinil)
- Department of Health and Social Care
- Health Technology Wales (HTW)
- NHS England
- Patient carer groups
- Action for Pulmonary Fibrosis
- Pulmonary Hypertension Association UK
- Professional groups
- Association of Respiratory Nurse Specialists
- British Thoracic Society
- Royal College of Physicians
- UK Clinical Pharmacy Association
- Associated public health groups
- None
- Comparator companies
- Amarox (sildenafil) (not signed, not participating)
- Aurobindo Pharma – Milpharm (sildenafil) (not signed, not participating)
- Brown and Burk UK (tadalafil) (not signed, not participating)
- Eli Lilly (tadalafil) (not signed, not participating)
- Mylan (tadalafil) (not signed, not participating)
- Pfizer (sildenafil) (not signed, not participating)
- Rosemont Pharmaceuticals (sildenafil) (not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 September 2025 | The appraisal committee meeting will now take place on 18 December 2025. |
| 10 March 2025 | Invitation to participate |
| 23 December 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-March 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late May 2025. |
| 12 December 2024 | Referral |
| 04 November 2024 - 02 December 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6459 |
| 04 November 2024 | In progress. Scoping commencing |
| 05 July 2024 | Topic selection |
| 02 July 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual